雜志介紹

Mabs雜志介紹

《Mabs》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱單克隆抗體，本刊主要出版、報道醫(yī)學(xué)-MEDICINE, RESEARCH & EXPERIMENTAL領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進展，探討行業(yè)發(fā)展的思路和方法，以促進學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為5.6，最新CiteScore 指數(shù)為10.7。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

  Author: Pang, Xinghua; Huang, Zhaoliang; Zhong, Tingting; Zhang, Peng; Wang, Zhongmin Maxwell; Xia, Michelle; Li, Baiyong

• High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions

  Author: Lourenco, Andre Luiz; Chuo, Shih-Wei; Bohn, Markus F.; Hann, Byron; Khan, Shireen; Yevalekar, Neha; Patel, Nitin; Yang, Teddy; Xu, Lina; Lv, Dandan; Drakas, Robert; Lively, Sarah; Craik, Charles S.

• Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer

  Author: Guan, Jiawei; Liu, Hongchuan; Chai, Yan; Yu, Jie; Yao, Jian; Wang, Jing; Pan, Zhiwei; Zhang, Jing; Zhou, Yuehua; Liu, Hui; Yao, Sheng; Qi, Jianxun; Feng, Hui; Gao, George. F. F.; Wang, Qihui; Shi, Yi; Tan, Shuguang

• Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.

  Author: Kuo WY¹, Hsu HJ¹, Wu CY², Chen HS¹, Chou YC¹, Tsou YL¹, Peng HP¹, Jian JW^1,3,4, Yu CM¹, Chiu YK¹, Chen IC¹, Tung CP¹, Hsiao M¹, Lin CL¹, Wang YA⁵, Wang AH⁶, Yang AS¹.

英文介紹

Mabs雜志英文介紹

mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.